- Home
- SLB vs MRNA Comparison
SLB vs MRNA Comparison
Compare SLB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLB | MRNA |
|---|---|---|
| Founded | 1926 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.3B | 61.6B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SLB | MRNA |
|---|---|---|
| Price | $49.96 | $187.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 30 | 23 |
| Target Price | $62.48 | ★ $119.56 |
| AVG Volume (30 Days) | 11.1M | ★ 12.0M |
| Earning Date | 10-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $30,440,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $3.53 | $8.08 |
| Revenue Next Year | $7.72 | $15.84 |
| P/E Ratio | $49.18 | ★ N/A |
| Revenue Growth | ★ 9.46 | 4.29 |
| 52 Week Low | $31.64 | $22.28 |
| 52 Week High | $60.46 | $208.90 |
Technical Indicators
Market Signals| Indicator | SLB | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 62.57 |
| Support Level | $48.32 | $43.35 |
| Resistance Level | $52.69 | N/A |
| Average True Range (ATR) | 1.45 | 13.32 |
| MACD | -0.38 | -0.47 |
| Stochastic Oscillator | 31.34 | 65.39 |
Price Performance
Historical ComparisonAbout SLB Schlumberger N.V.
SLB is the world's premier oilfield-services company as measured by market share. While the industry is largely fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies in which it operates. Also known as Schlumberger, the company was founded in 1926 by Conrad and Marcel Schlumberger. Today, it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: core, digital, and new energy businesses. Over three-fourths of its revenue base is tied to international markets, while the company boasts nearly $3 billion in digital-related revenue.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.